New malaria vaccine passes early safety test in kids

NCT ID NCT05155579

Completed ⭐️ VACCINE ⭐️ Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the R21/Matrix-M malaria vaccine in 594 children aged 5 to 36 months in Mali. Researchers checked if the vaccine is safe and triggers an immune response, both when given alone and alongside routine childhood vaccines like measles and yellow fever. The goal is to find the best way to give the vaccine in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: R21/Matrix-M malaria vaccine
What this could lead to: If successful, this could help develop a practical malaria vaccine that works alongside routine childhood immunizations.
What could go wrong: This is an early Phase Ib safety trial, not designed to prove the vaccine prevents malaria. Results may not lead to a licensed vaccine.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malaria prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALARIA

Contacts and locations

Locations

CCVTM, University of Oxford

Oxford, United Kingdom
Malaria Research & Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, University of Sciences Techniques and Technologies of Bamako

Bamako, Mali

More trials for these conditions

Other studies related to the condition(s) this trial covers.